# CAMP4 Therapeutics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/camp4-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.camp4tx.com
- Total disclosed funding: $179M
- Latest round: Series B (Jun 3, 2022)
- Investors on record: 7

## About

CAMP4 Therapeutics Corporation, based in Cambridge, US, specializes in developing RNA-based therapies designed to restore gene expression and address various genetic disorders and diseases.CAMP4 Therapeutics Corporation focuses on innovating RNA therapies to tackle genetic diseases. Founded in 2016 in Cambridge, US, by Leonard Zon and Richard Young, the company has undergone strategic pivots to enhance its research and product offerings. CAMP4 recently secured USD 100.000 mn in a Series B funding round led by Enavate Sciences, contributing to a total amount raised of USD 100.000 mn. The company is currently valued at approximately USD 245.938 mn.CAMP4 specializes in innovative RNA treatments aimed at correcting gene expression to combat genetic disorders. Its offerings target both rare and common ailments, catering primarily to healthcare institutions and research facilities across North America and Europe.In 2022, CAMP4 reported no revenue. For the year 2023, the company recorded an EBITDA of USD -50,201,000, reflecting its ongoing investment in research and development.Following a recent IPO on October 10, 2024, CAMP4 Therapeutics Corporation raised USD 75 mn by selling 6.82 million shares at USD 11 per share. The funds will support the launch of new RNA therapies and potential market expansion into Asia and South America by 2025. The IPO listing valued the company at approximately USD 280 mn and included a 30-day option for underwriters to purchase additional shares.

## Funding rounds

- Series B, Jun 3, 2022, $100M — Polaris Partners, 5AM Ventures, Andreessen Horowitz, Kraft Group, Gaingels, Northpond Ventures, Enavate Sciences
- Series A, Mar 5, 2021, $45M — Polaris Partners, 5AM Ventures, Andreessen Horowitz, Kraft Group, Northpond Ventures
- Series A, Apr 20, 2018, $34M — Polaris Partners, Andreessen Horowitz, Kraft Group

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B
- Kraft Group — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B
- Enavate Sciences — Series B